Shandong Keyuan Pharmaceutical Co Ltd
SZSE:301281
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Shandong Keyuan Pharmaceutical Co Ltd
Long-Term Debt
Shandong Keyuan Pharmaceutical Co Ltd
Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
Shandong Keyuan Pharmaceutical Co Ltd
SZSE:301281
|
Long-Term Debt
¥112.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Long-Term Debt
¥47.6m
|
CAGR 3-Years
-78%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
N/A
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Long-Term Debt
¥43.3m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Long-Term Debt
¥779.6m
|
CAGR 3-Years
39%
|
CAGR 5-Years
84%
|
CAGR 10-Years
-1%
|
|
|
Zhejiang Nhu Co Ltd
SZSE:002001
|
Long-Term Debt
¥4.2B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
0%
|
CAGR 10-Years
46%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Long-Term Debt
¥1.2B
|
CAGR 3-Years
129%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Shandong Keyuan Pharmaceutical Co Ltd
Glance View
Shandong Keyuan Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of chemical raw materials, and chemical preparation. The company is headquartered in Jinan, Shandong. The company went IPO on 2023-04-04. The firm's main products include gliclazide, metformin hydrochloride, ropivacaine hydrochloride and others. The firm's products are used in hypoglycemic, anesthetic, cardiovascular and psychiatric diseases. The firm conducts its operations mainly in the domestic market.
See Also
What is Shandong Keyuan Pharmaceutical Co Ltd's Long-Term Debt?
Long-Term Debt
112.3m
CNY
Based on the financial report for Dec 31, 2025, Shandong Keyuan Pharmaceutical Co Ltd's Long-Term Debt amounts to 112.3m CNY.
What is Shandong Keyuan Pharmaceutical Co Ltd's Long-Term Debt growth rate?
Long-Term Debt CAGR 1Y
146%
Over the last year, the Long-Term Debt growth was 146%.
